Objective. To assess the relationship between skeletal muscle index (SMI) and the frequency, nature, and severity of toxic complications in patients with locally advanced and metastatic gastric cancer during antitumor drug therapy, a study is being conducted Material and methods. The study included 100 patients diagnosed with gastric cancer who had undergone four courses of chemotherapy. Computed tomography was used for sarcopenia diagnosis. SMI was calculated as the ratio of the average skeletal muscle area at the L3 level to the square of the patient’s height. The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 scale was used to assess the severity of adverse events. Results. Correlation analysis showed a moderate, inverse, statistically significant relationship (p0.05) with SMI before treatment and after four courses of chemotherapy. Conclusion. The presence of sarcopenia in patients with gastric cancer may serve as a predictor of an increase in the severity of toxicity of antitumor drug therapy. The routinely used bode mass index and body surface area during treatment are not reliable markers for predicting toxicity.
Петроченко et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: